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ABSTRACT
The aim of this study was to explore the cost-effectiveness of short protocols including different
types of gonadotropins for controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF).
A retrospective, observational study of the real-life practice in a specialized IVF gynaecology clinic
in 20092013 was carried out. All women on short COH protocols were recruited into three
groups: COH including recombinant follicle stimulating hormone (rFSH) and urinary-FSH (urFSH)
(n D 173); including urFSH alone (n D 289); and including rFSH alone (n D 212). The cost-
effectiveness of the COH protocols was explored in two different case scenarios for possible
outcomes. The ﬁrst case scenario took into consideration a successful live birth, and the second
one, the women to achieve pregnancy with live birth. Decision modelling was done using the
TreeAge 2014 Software. According to the results in the ﬁrst case scenario, the rFSH plus urFSH COH
approach showed the highest weighted probability (p D 0.38) of live birth, but the urFSH
alternative was cost-effective. The results in the second case scenario demonstrated that the urFSH
protocol was again the cost-effective alternative. These results suggest that the strategy with urFSH
should be preferred in both cases, but rFSH could also be considered as a cost-effective alternative
for successful live birth and achieving pregnancy and delivery, since the incremental cost-
effectiveness ratio in comparison with the urFSH protocol is below the gross domestic product per










Ovarian stimulation is the critical part of the medication
management of in vitro fertilization (IVF) therapy.[1] A
variety of efﬁcacious controlled ovarian hyperstimulation
(COH) regimens are used, but their cost-effectiveness
needs to be further explored in terms of individualized
management of successful pregnancy and delivery.
Development of biotechnologically derived recombinant
products also contributes to the success of IVF.[26]
A cost-effectiveness study on the higher efﬁcacy of folli-
tropin-beta, a new recombinant follicle stimulating hor-
mone (rFSH), versus urinary-FSH (urFSH), found that the
incremental cost-effectiveness ratio (ICER) varies from 19.2
to 26.0 million Italian lire (11 300 $US and 15 400 $US)
depending on the setting and the type of treatment.[7]
The cost-effectiveness and economic aspects of the IVF
methods have been explored after transfer of one or two
embryos.[8,9] Comparative analysis in terms of cost-effec-
tiveness has been performed on rFSH versus urFSH by
using modelling techniques [10,11], as well as on three
gonadotropin treatments: with rFSH, highly puriﬁed urFSH
and human menopausal gonadotropins (hMGT), by also
exploring the possibility for IVF failure.[12]
This study was based on the recommendations by
Garceau et al. [13] that the cost-effectiveness of different
interventions should be considered when making deci-
sions about treatment, especially in health-care settings
with limited budgets. The aim of the study was to
explore the cost-effectiveness of three short COH proto-
cols including different types of gonadotropins for IVF.
The ﬁrst one is a combination of rFSH (follitropin-alfa or
follitropin-beta) and urFSH (highly puriﬁed human FSH/
highly puriﬁed hMGTs), the second one is with urFSH
only and the third one is with rFSH only. The study was
performed from the point of view of the IVF clinic for a
period of ﬁve years. It addressed the question of which
of the studied COH approaches is cost-effective resulting
in (1) live-born children and (2) women with pregnancies
and live birth.
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Subjects and methods
Study cohort and design
A retrospective, observational study of the real-life prac-
tice in a specialized IVF gynaecology clinic in 20092013
was carried out. Information was collected about the
short protocol COH approaches used in the clinic for all
patients admitted during the period. All women with
short protocols of COH (n D 674) out of all 685 admitted
women were recruited into three groups according to
the type of follicular stimulating hormone (FSH) included
in the short COH protocols as follows (Table 1): COH
including rFSH and urFSH (n D 173), COH including
urFSH alone (n D 289) and COH including rFSH alone (n
D 212). All patients gave their informed consent. The
study complied with the ethical guidelines of the Medi-
cal University of Soﬁa.
All other medicines included in the protocols were
also systematized. A record was kept of the number of
live-born children and women with live birth. Due to
multiple pregnancies, in some cases the numbers differ
(Table 2). Within the framework of the chosen setting, an
attempt was made to identify which of the adopted
practices gave better results.
The choice of stimulation short protocol was made
primarily based on (1) the individual characteristics of
the patient (age, habitat, ovarian reserve, BMI (body
mass index), presence of polycystic ovary syndrome
(PCOS),[14] ovarian response to stimulation during a pre-
vious cycle (if available)); (2) price of medicines; and (3)
experience and preferences of the physician leading the
stimulation. In the observed clinic, only one team of
physicians was responsible for ovarian stimulation and,
therefore, there were considered to be no differences in
the experience. Every woman in the study was assigned
to a particular COH protocol group based on the above-
mentioned criteria and the real-life choice of the
physician.
Modelling
To explore the cost-effectiveness of the studied COH
approaches, two scenarios were designed. The decision
tree model was built using TreeAge 2014 software. The
ﬁrst step was to create the model framework for the two
scenarios. The model was used to analyse the three COH
approaches as compared with therapeutic alternatives
and expected results.
The ﬁrst case scenario was designed to take into con-
sideration only the criterion successful child delivery
(number of live-born children). For each COH alternative,
two possible chance node outcomes were considered,
i.e. delivery (live birth) or no delivery. The second case
scenario was created to explore the cost-effectiveness of
Table 1. Description of the studied COH protocols.
Protocols
rFSH and urFSH urFSH rFSH
A combination of follitropin-beta (rFSH) C urofollitropin  highly
puriﬁed human FSH (urFSH)
Urofollitropin alone Follitropin-alfa alone
or or or
A combination of follitropin-beta (rFSH) C urofollitropin: luteinising
hormone (75 IU:75 IU)  highly puriﬁed menopausal
gonadotropins (urFSH)
Urofollitropin: luteinising hormone (75 IU:75 IU) alone Follitropin-beta alone
or
A combination of urofollitropin  highly puriﬁed human
FSH (urFSH)C urofollitropin: luteinising hormone (75
IU:75 IU)  highly puriﬁed menopausal gonadotropins
(urFSH)
Table 2. Characteristics of the study cohort.
Type of COH
Indicator rFSH and urFSH urFSH rFSH
Total number of treated women 173 289 212
Pregnancy rates (%) 46 (26.6%) 82 (28.3%) 57 (26.9%)
Live birth rates (%) 46 (26.6%) 52 (17.9%) 60 (28.3%)
Number of deliveries (%) 32 (18.5%) 46 (15.9%) 47 (22.2%)
Number of undelivered women 141 243 165
Number of live births per woman with delivery 1.44 1.13 1.28
Number of triplets 1
Number of twins 12 6 13
Singleton deliveries 19 40 21
Probability of child delivery 0.2659 0.1799 0.2830
Probability of a woman to deliver 0.1850 0.1591 0.2217
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the three COH approaches in regard to conceiving and
delivering (live birth). In this scenario, the chance nodes
were women with delivery (live birth) and no delivery
(Figure 1).
Data analysis
The average cost and standard deviation (SD) of the
three COH approaches in the model were calculated for
each chance node: group on rFSH and urFSH with deliv-
ery (live birth) and no delivery; group with urFSH with
delivery (live birth) and no delivery; group with rFSH
with delivery (live birth) and no delivery, for the ﬁrst case
scenario on the basis of the real-life data in the clinic for
a ﬁve-year period. Information about the prices of all
medicines included in the COH protocols for each
woman was gathered from the positive drug list at the
2014 price level in the local currency (exchange rate 1
BGN D 0.95 Euro).[15] After deﬁning the groups, the
average cost per protocol was calculated (Table 3).
In the ﬁrst case scenario, probabilities were derived
considering the live-born children in the clinic in each of
the compared alternatives. In the second case scenario,
the probability of a woman conceiving and delivering
was considered instead. Only live births were considered
in both scenarios.
The results are presented as number of live-born chil-
dren for each alternative. ICER was calculated using the
classical formula [16] and the cost-effectiveness plate
was built.
Results and discussion
Various types of COH protocols have been developed for
the purposes of assisted reproductive technologies, but
two of them are seen as the ‘gold standard’: a long pro-
tocol with gonadotropin-releasing hormone agonist
(GnRH agonist) and a short protocol with (gonadotropin-
releasing hormone antagonist (GnRH antagonist). With
the emergence of GnRH antagonists in the last century,
the short antagonist protocol is gaining popularity, as it
has a few advantages over the long protocol with a
GnRH agonist. The advantages are that it is a short, sim-
ple and convenient method of stimulation which is well
tolerated by the patient; it gives the possibility to reduce
the dose of gonadotropins and to minimize the risk of
side effects; there is decreased risk of ovarian hyperstim-
ulation syndrome (OHSS); the method provides patient
comfort and better clinical results of IVF cycles, which
are comparable with those achievable via long protocols
with a GnRH agonist.[1719] In this study, three short
COH protocols were analysed from the point of view of
cost-effectiveness, since the results could differ depend-
ing on the medicines used for COH. The ﬁrst one is a
combination of rFSH (follitropin-alfa or follitropin-beta)
and urFSH (highly puriﬁed human FSH/highly puriﬁed
Figure 1. Cost-effectiveness tree in the ﬁrst case scenario.
Table 3. Cost of COH protocols.
Type of cost Cost in BGN (rFSH and urFSH) Cost in BGN (urFSH) Cost in BGN (rFSH)
Average cost of COH 1986.46 § 826.02 1422.08 § 655.49 1627.73 § 545.54
Average cost of COH per delivered women 1765.27 § 693.99 1267.51 § 592.60 1474.85 § 489.18
Average cost of COH per undelivered women 2036.66 § 842.26 1475.13 § 661.55 1671.28 § 551.99
Note: Data are mean values with standard deviation (§ SD).
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human menopausal gonadotropins), the second one is
with urFSH only and the third one is with rFSH only.
Short COH protocols
The three short COH protocols as alternative approaches
are presented in Table 1. The choice of the COH protocol
and the combination of medicines depends on the indi-
vidual characteristics of each patient: age, habitat, ovarian
reserve, BMI, presence of PCOS,[14] and ovarian response
to stimulation during a previous cycle (if data were avail-
able). The three groups in this study were deﬁned based
on the groups of medicines included in the short COH
protocols: recombinant gonadotropins, urinary gonadotro-
pins or a combination of both. The possible sub-combina-
tions of medicines within these three groups that were
used in the stimulation protocols are also given in Table 1.
Different combinations were applied in each group
for patients with poor ovarian response. The characteris-
tics of the compared groups of women are given in
Table 2. The majority of women received urFSH, which is
the least costly COH approach, but with the lowest prob-
ability of live birth and of women conceiving and deliver-
ing (live birth). On the other hand, this approach led to a
relatively high share of pregnancies (28.3%). The highest
probability of child delivery and of women conceiving
and delivering was observed in the group on rFSH.
The results from the cost analysis showed that the
cost of COH was the highest in the group of women
treated with a combination of rFSH and urFSH (Table 3),
which is not surprising, given the higher cost of combi-
nation therapy. The approach that uses rFSH ranked
second in terms of costs, and the urFSH protocol ranked
third.
The average cost of COH in the case of undelivered
women was shown to be higher. This could probably be
due to poor ovarian response in these women, since
women with poor ovarian response require more medi-
cines and longer time for stimulation, which naturally
incurs higher costs.
First case scenario (number of live-born children)
The basic decision tree for the ﬁrst case scenario showed
that the alternative COH approach which includes rFSH
and urFSH is with the highest weighted probability
(p D 0.38) of live birth. When the costs were added to
the analysis and the cost-effectiveness was calculated,
the obtained results indicated that the alternative with
urFSH should be the preferred one from the viewpoint
of the number of delivered live-born children (Figure 1).
The urFSH alternative was shown to be the cost-effec-
tive choice from the perspective of live-born children
(Figure 2).
The ICER for the rFSH alternative could also be consid-
ered as acceptable from the point of view of the gynae-
cology clinic (Table 4). It falls far below the accepted
threshold for the gross domestic product (GDP) per cap-
ita.[20]
Second case scenario (number of women to conceive
and give live birth)
In the second case scenario, we observed that the alter-
native COH approach including rFSH is with the highest
weighted probability (p D 0.28) of women conceiving
Figure 2. Cost-effectiveness plate in the ﬁrst case scenario.
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and delivering (one or more) live-born child. When the
analysis was extended to take into consideration the
costs and the cost-effectiveness of the alternatives, again
the urFSH stood out as the choice to be preferred from
the point of view of women conceiving and delivering a
live-born child (Figure 3).
The urFSH protocol was shown to be the least costly
alternative but with the lowest weighted probability of
success for a woman to conceive and successfully give
birth in this case scenario (Figure 4).
The ICER for the rFSH approach in the second case
scenario is also below the recommended threshold of
GDP per capita and can be considered a cost-effective
alternative (Table 5). In this scenario, the alternative with
rFSH and urFSH is dominated by the rFSH alternative
because the combination has higher cost and lower
probability of success. Thus, the alternative with rFSH
and urFSH is not likely to be recommended from the
point of view of the IVF clinic (Table 5).
Comparative analysis
In a variety of healthcare settings, short protocols are
connected with decreased overall cost of treatment.
Based on the data accumulated on a global scale and
our clinics’ experience, we suggest the short protocol
with a GnRH antagonist as more appropriate and this
can explain the majority of patients treated with short
protocols. This experience is also in line with the results
from randomized clinical trials, which have shown that
the short protocol with a GnRH antagonist is the ﬁrst
choice in IVF programmes, with fewer complications,
reduced risk of OHSS and sufﬁcient success.[17,21]
In all types of stimulation protocols, ovarian stimula-
tion is performed with gonadotropins (FSH products: uri-
nary, recombinant or a combination of both). In recent
years, many studies and debates have been conducted
on the effectiveness of rFSH compared to urFSH. A study
in 2001 reported a greater percentage of clinical preg-
nancies when using urFSH as compared to rFSH.[18]
Based on the contrasting data published in the following
years, 10 years later, the same authors reported their key
Cochrane study comparing the effectiveness of rFSH to
that of three types of urFSH.[19] The results showed no
difference in the performance of different FSH products
in terms of clinical pregnancies, live births and safety,
both in fresh and frozen IVF cycles.[22,23]
Regarding the questions addressed in our study, the
results suggest that the urFSH strategy should be
preferred as the most cost-effective alternative in both
case scenarios because the cost per unit of result is
lower. The rFSH alternatives could also be considered
cost-effective in terms of the number of delivered live-
born children as well as in terms of the number of
women with successful conception and delivery because
the ICER is below the GDP per capita threshold
Table 4. ICER table in the ﬁrst case scenario.






effectiveness (prob.) C/E ICER
urFSH 1437.78 0.2033 7072.21
rFSH 1615.69 177.91 0.3622 0.1589 4460.77 1119.27
rFSH and urFSH 1964.52 348.83 0.3827 0.0205 5133.32 17,006.10
Figure 3. Cost-effectiveness tree in the second case scenario.
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recommended by health economists.[16] The rFSH and
urFSH combination approach was shown not to be cost-
effective in both explored scenarios from the point of
view of the clinic.
Short stimulation protocols including only urFSH are
applied mainly in patients of advanced maternal
age (over 35 years) and those with reduced ovarian
reserve (FSH levels less than 15 mIU/mL, anti-M€ullerian
hormone levels under 0.81 ng/mL and 23 antral fol-
licles in each ovary). The practice of applying short proto-
cols in women aged over 35 years has been
recommended in several studies.[2426] The higher bio-
logical activity of urinary products is necessary in extreme
cases, when stronger stimulation is required, i.e. in
patients of advanced maternal age and those with
reduced ovarian reserve. The price of urinary products is
also important in these cases and high doses of FSH are
needed to achieve satisfactory results.
The frequent choice of urFSH as a COH strategy could
be explained by the individual patients’ characteristics
(age over 35 years, reduced ovarian reserve) as well as
by the lowest average cost of this alternative in compari-
son with the other two approaches. These results
conﬁrm the conclusions of other authors [27,28] that, in
choosing the COH strategy, it is necessary to individual-
ize the approaches considering a variety of factors, and
not only the cost of COH.
Our study, however, has some limitations: it was only
focused on COH medication therapy and did not explore
other factors, such as physicians’ experience, different
settings among the clinical centres, etc. The reasoning
behind the choice of factors to be analysed was based
on the aim to optimize the future choices for COH by
also considering the probability of successful pregnancy
and delivery. Although our study was a retrospective
analysis, the results would aid future therapeutic deci-
sions in cases of doubt as to which strategy would most
likely be successful or cost-effective.
Conclusions
The results from this study indicated that the strategy
with urFSH should be further preferred in both case sce-
narios (live-born children or women who conceive and
give live birth). rFSH could also be considered as a cost-
effective alternative in both these case scenarios
Figure 4. Cost-effectiveness plate in the second case scenario.
Table 5. ICER table in the second case scenario.






effectiveness (prob.) C/E ICER
urFSH 1442.10 0.1798 8020.58
rFSH 1627.73 185.63 0.2838 0.1040 5735.48 1784.90
rFSH and urFSH 1986.45 358.72 0.2645 -0.0192 7510.21 Dominated
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because the ICER in comparison with urFSH is below the
GDP per capita. The combination approach of rFSH and
urFSH was shown not to be cost-effective in both
explored scenarios from the point of view of the clinic.
Although the conclusions are valid only for the particular
clinic observed in our study, they could also be used in
making therapeutic decisions by any other IVF clinic
with similar therapeutic practices.
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